Q-omics provides the consensus-scored RAD51AP2 profile across patient tissues and cancer cell-line models. RAD51AP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAD51AP2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RAD51AP2 RNA expression shows 14,584 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where RAD51AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD51AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD51AP2 survival associations across molecular data types. RAD51AP2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD51AP2 RNA expression–survival associations across cancer types. High RAD51AP2 expression shows unfavorable associations in KIRC, UVM, LUAD, ACC and THCA, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAD51AP2 RNA expression.
This table summarizes RAD51AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RAD51AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD51AP2 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LUSC, COAD and LIHC. The KIRC box plot shows higher RAD51AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.037, t-test p < 0.001).
This table shows molecular features associated with RAD51AP2 in patient tissues and cancer cell lines. In patient samples, RAD51AP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD51AP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
